Alnylam Pharmaceuticals | Betriebsaufwand



Operating Expenses Veränderung Datum
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Arrowhead Research USD 163.91M 1.71M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Incyte USD 877.18M 114.6M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
Moderna USD 2.21B 280M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 10.15B 579M 2024-12
PTC Therapeutics USD 275.66M 24.36M 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Sanofi EUR 10.52B 1.42B 2024-09
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Takeda JPY 1.08T 85.39B 2024-12
Tectonic Therapeutic USD 19.64M 8.22M 2024-09
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12
Xencor USD 65.97M 7.02M 2024-12



Alnylam Pharmaceuticals Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.